Franz Koenig

Follow

Generating author description...

All published works
Action Title Year Authors
+ A general consonance principle for closure tests based on p-values 2024 Sonja Zehetmayer
Franz Koenig
Martin Posch
+ PDF Chat Treatment-control comparisons in platform trials including non-concurrent controls 2024 Marta Bofill Roig
Pavla Krotka
Katharina Hees
Franz Koenig
Dominic Magirr
Peter Jacko
Tom Parke
Martin Posch
+ PDF Chat A Review of EMA Public Assessment Reports where Non-Proportional Hazards were Identified 2024 Florian Klinglmueller
Norbert Benda
Tim Friede
Tobias Fellinger
Harald Heinzl
Andrew C. Hooker
Franz Koenig
Tim Mathes
Martin Posch
Florian Stampfer
+ PDF Chat Current state-of-the-art and gaps in platform trials: 10 things you should know, insights from EU-PEARL 2023 Franz Koenig
CĂ©cile Spiertz
Daniel Millar
Sarai RodrĂ­guez
NĂșria MachĂ­n
Ann Van Dessel
Joan GenescĂ 
Juan M. PericĂ s
Martin Posch
Adrián Sánchez‐Montalvá
+ PDF Chat Developing Generic Templates to Shape the Future for Conducting Integrated Research Platform Trials 2023 Peter Mesenbrink
Madhavi Gidh‐Jain
Tom Parke
Franz Koenig
CĂ©cile Spiertz
+ SIMPLE—A modular tool for simulating complex platform trials 2023 Elias Laurin Meyer
Tobias Mielke
Tom Parke
Peter Jacko
Franz Koenig
+ PDF Chat On the use of non-concurrent controls in platform trials: a scoping review 2023 Marta Bofill Roig
Cora Burgwinkel
Ursula Garczarek
Franz Koenig
Martin Posch
Quynh Nguyen
Katharina Hees
+ PDF Chat An interactive R-Shiny app for quickly visualizing a tidy, long dataset with multiple dimensions with an application in clinical trial simulations for platform trials 2023 Elias Laurin Meyer
Constantin Kumaus
Michal Majka
Franz Koenig
+ Platform trials to overcome major shortcomings of traditional clinical trials in non-alcoholic steatohepatitis? Pros and cons 2022 Juan M. PericĂ s
Frank Tacke
Quentin M. Anstee
Nicholas A. Di Prospero
Mette SkalshĂžj KjĂŠr
Peter Mesenbrink
Franz Koenig
Joan GenescĂ 
Vlad Ratziu
+ Online control of the False Discovery Rate in group-sequential platform trials 2022 Sonja Zehetmayer
Martin Posch
Franz Koenig
+ PDF Chat Adaptive clinical trial designs with blinded selection of binary composite endpoints and sample size reassessment 2022 Marta Bofill Roig
Guadalupe GĂłmez Melis
Martin Posch
Franz Koenig
+ PDF Chat On model-based time trend adjustments in platform trials with non-concurrent controls 2022 Marta Bofill Roig
Pavla Krotka
Carl‐Fredrik Burman
Ekkehard Glimm
Stefan M. Gold
Katharina Hees
Peter Jacko
Franz Koenig
Dominic Magirr
Peter Mesenbrink
+ On the use of non-concurrent controls in platform trials: A scoping review 2022 Marta Bofill Roig
Cora Burgwinkel
Ursula Garczarek
Franz Koenig
Martin Posch
Quynh Nguyen
Katharina Hees
+ On model-based time trend adjustments in platform trials with non-concurrent controls 2021 Marta Bofill Roig
Pavla Krotka
Carl‐Fredrik Burman
Ekkehard Glimm
Katharina Hees
Peter Jacko
Franz Koenig
Dominic Magirr
Peter Mesenbrink
Kert Viele
+ Online control of the False Discovery Rate in group-sequential platform trials 2021 Sonja Zehetmayer
Martin Posch
Franz Koenig
+ PDF Chat Endpoints for randomized controlled clinical trials for COVID-19 treatments 2020 Lori E. Dodd
Dean Follmann
Jing Wang
Franz Koenig
Lisa L. Korn
Christian Schoergenhofer
Michael A. Proschan
Sally Hunsberger
Tyler Bonnett
Mat Makowski
+ Efficient Adaptive Designs for Clinical Trials of Interventions for COVID-19 2020 Nigel Stallard
Lisa V. Hampson
Norbert Benda
Werner Brannath
Thomas Burnett
Tim Friede
Peter Kimani
Franz Koenig
Johannes Krisam
Pavel Mozgunov
+ PDF Chat The Adaptive designs CONSORT Extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design 2020 Munyaradzi Dimairo
Philip Pallmann
James Wason
Susan Todd
Thomas Jaki
Steven A. Julious
Adrian Mander
Christopher J. Weir
Franz Koenig
Marc K. Walton
+ PDF Chat The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design 2020 Munyaradzi Dimairo
Philip Pallmann
James Wason
Susan Todd
Thomas Jaki
Steven A. Julious
Adrian Mander
Christopher J. Weir
Franz Koenig
Marc K. Walton
+ Endpoints for randomized controlled clinical trials for COVID-19 treatments 2020 Lori E. Dodd
Dean Follmann
Jing Wang
Franz Koenig
Lisa L. Korn
Christian Schoergenhofer
Michael A. Proschan
S. Hunsberger
Tyler Bonnett
Mat Makowski
+ Efficient adaptive designs for clinical trials of interventions for COVID-19 2020 Nigel Stallard
Lisa V. Hampson
Norbert Benda
Werner Brannath
Tom Burnett
Tim Friede
Peter Kimani
Franz Koenig
Johannes Krisam
Pavel Mozgunov
+ Model-based simultaneous inference for multiple subgroups and multiple endpoints 2020 Charlotte Vogel
Frank Schaarschmidt
Christian Ritz
Franz Koenig
Ludwig A. Hothorn
+ Efficient adaptive designs for clinical trials of interventions for COVID-19 2020 Nigel Stallard
Lisa V. Hampson
Norbert Benda
Werner Brannath
Thomas Burnett
Tim Friede
Peter Kimani
Franz Koenig
Johannes Krisam
Pavel Mozgunov
+ Endpoints for randomized controlled clinical trials for COVID-19 treatments 2020 Lori E. Dodd
Dean Follmann
Jing Wang
Franz Koenig
Lisa L. Korn
Christian Schoergenhofer
Michael A. Proschan
S. Hunsberger
Tyler Bonnett
Mat Makowski
+ Efficient adaptive designs for clinical trials of interventions for COVID-19 2020 Nigel Stallard
Lisa V. Hampson
Norbert Benda
Werner Brannath
Tom Burnett
Tim Friede
Peter Kimani
Franz Koenig
Johannes Krisam
Pavel Mozgunov
+ PDF Chat Are Novel, Nonrandomized Analytic Methods Fit for Decision Making? The Need for Prospective, Controlled, and Transparent Validation 2019 Hans‐Georg Eichler
Franz Koenig
Peter Arlett
Harald Enzmann
A. J. B. Humphreys
Frank PĂ©tavy
Brigitte Schwarzer‐Daum
Bruno Sepodes
Spiros Vamvakas
Guido Rasi
+ Group sequential adaptive designs in series of time-to-event randomised trials in rare diseases: A simulation study 2019 Mohamed Amine Bayar
Gwénaël Le Teuff
Franz Koenig
Marie‐CĂ©cile Le Deley
Stefan Michiels
+ PDF Chat The Adaptive designs CONSORT Extension (ACE) Statement: A checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design 2019 Munyaradzi Dimairo
Philip Pallmann
James Wason
Susan Todd
Thomas Jaki
Steven A. Julious
Adrian Mander
Christopher J. Weir
Franz Koenig
Marc K. Walton
+ PDF Chat Response to comments on Jaki et al., A proposal for a new PhD level curriculum on quantitative methods for drug development. Pharm Stat17(5):593‐606, Sep/Oct 2018., DOI: https://doi.org/10.1002/pst.1873 2019 Thomas Jaki
Allan Gordon
Pamela Forster
Luc Bijnens
Bjoern Bornkamp
Werner Brannath
Roberto Fontana
Mauro Gasparini
Lisa V. Hampson
Tom Jacobs
+ PDF Chat Adaptive designs in clinical trials: from scientific advice to marketing authorisation to the European Medicine Agency 2018 Olivier Collignon
Franz Koenig
Armin Koch
Robert Hemmings
Frank PĂ©tavy
AgnĂšs Saint-Raymond
Marisa Papaluca‐Amati
Martin Posch
+ PDF Chat Development process of a consensus-driven CONSORT extension for randomised trials using an adaptive design 2018 Munyaradzi Dimairo
Elizabeth Coates
Philip Pallmann
Susan Todd
Steven A. Julious
Thomas Jaki
James Wason
Adrian Mander
Christopher J. Weir
Franz Koenig
+ PDF Chat Design and estimation in clinical trials with subpopulation selection 2018 Yi‐Da Chiu
Franz Koenig
Martin Posch
Thomas Jaki
+ PDF Chat A proposal for a new PhD level curriculum on quantitative methods for drug development 2018 Thomas Jaki
A. Gordon
Patricia Forster
Luc Bijnens
Bjoern Bornkamp
Werner Brannath
Roberto Fontana
Mauro Gasparini
L Hampson
Tom Jacobs
+ Flexible alpha allocation strategies for confirmatory adaptive enrichment clinical trials with a prespecified subgroup 2018 Toshifumi Sugitani
Martin Posch
Frank Bretz
Franz Koenig
+ PDF Chat An update on the clinical evidence that supports biosimilar approvals in Europe 2018 Johanna Mielke
Bernd Jilma
Byron Jones
Franz Koenig
+ Permutational Group Sequential Test for Time-to-Event Data [R package permGS version 0.2.5] 2017 Matthias Brueckner
Martin Posch
Franz Koenig
+ PDF Chat Many-to-one comparisons after safety selection in multi-arm clinical trials 2017 Gerald Hlavin
Lisa V. Hampson
Franz Koenig
+ PDF Chat “Threshold‐crossing”: A Useful Way to Establish the Counterfactual in Clinical Trials? 2016 H‐G Eichler
Brigitte Bloechl‐Daum
Philipp K. Bauer
Frank Bretz
Jeffrey S. Brown
L Hampson
Peter K. Honig
Michael Krams
Hubert G.M. Leufkens
Robyn Lim
+ PDF Chat Clinical trials for authorized biosimilars in the European Union: a systematic review 2016 Johanna Mielke
Bernd Jilma
Franz Koenig
Byron Jones
+ PDF Chat Sample Size Reassessment and Hypothesis Testing in Adaptive Survival Trials 2016 Dominic Magirr
Thomas Jaki
Franz Koenig
Martin Posch
+ PDF Chat Evidence, eminence and extrapolation 2016 Gerald Hlavin
Franz Koenig
Christoph Male
Martin Posch
PĂ©ter Bauer
+ PDF Chat Adaptive two-stage bioequivalence trials with early stopping and sample size re-estimation 2015 Franz Koenig
Martin J. Wolfsegger
Thomas Jaki
Helmut SchĂŒtz
Gernot Wassmer
+ PDF Chat Adaptive designs for subpopulation analysis optimizing utility functions 2014 Alexandra GrĂĄf
Martin Posch
Franz Koenig
+ PDF Chat Adaptive graph‐based multiple testing procedures 2014 Florian Klinglmueller
Martin Posch
Franz Koenig
+ PDF Chat Adaptive clinical trial designs for European marketing authorization: a survey of scientific advice letters from the European Medicines Agency 2014 Amelie ElsĂ€ĂŸer
Jan Regnström
Thorsten Vetter
Franz Koenig
Robert Hemmings
Martina Greco
Marisa Papaluca‐Amati
Martin Posch
+ PDF Chat Sharing clinical trial data on patient level: Opportunities and challenges 2014 Franz Koenig
Jim Slattery
Trish Groves
Thomas Lang
Yoav Benjamini
Simon Day
PĂ©ter Bauer
Martin Posch
+ Adaptive Survival Trials 2014 Dominic Magirr
Thomas Jaki
Franz Koenig
Martin Posch
+ PDF Chat Maximum type 1 error rate inflation in multiarmed clinical trials with adaptive interim sample size modifications 2014 Alexandra GrĂĄf
PĂ©ter Bauer
Ekkehard Glimm
Franz Koenig
+ Adaptive Survival Trials 2014 Dominic Magirr
Thomas Jaki
Franz Koenig
Martin Posch
+ Role of modeling and simulation in pediatric investigation plans 2011 Efthymios Manolis
Tariq Eldirdiry Osman
Ralf Herold
Franz Koenig
P. Tomasi
Spiros Vamvakas
AgnĂšs Saint-Raymond
+ Factors associated with success of market authorisation applications for pharmaceutical drugs submitted to the European Medicines Agency 2009 Jan Regnström
Franz Koenig
B. Aronsson
Tatiana Reimer
Kristian Svendsen
Stelios Tsigkos
Bruno Flamion
Hans‐Georg Eichler
Spiros Vamvakas
+ Selection and bias—Two hostile brothers 2009 PĂ©ter Bauer
Franz Koenig
Werner Brannath
Martin Posch
+ Optimal choice of the number of treatments to be included in a clinical trial 2009 Nigel Stallard
Martin Posch
Tim Friede
Franz Koenig
Werner Brannath
+ Adaptive designs for confirmatory clinical trials 2009 Frank Bretz
Franz Koenig
Werner Brannath
Ekkehard Glimm
Martin Posch
+ MCP2007 – 5th International Conference on Multiple Comparison Procedures 2008 Martin Posch
Franz Koenig
Jason C. Hsu
+ Adaptive Dunnett tests for treatment selection 2007 Franz Koenig
Werner Brannath
Frank Bretz
Martin Posch
+ Multiplicity and flexibility in clinical trials 2007 Werner Brannath
Franz Koenig
PĂ©ter Bauer
+ PDF Chat Testing and estimation in flexible group sequential designs with adaptive treatment selection 2005 Martin Posch
Franz Koenig
Michael Branson
Werner Brannath
Cornelia Dunger‐Baldauf
PĂ©ter Bauer
+ The reassessment of trial perspectives from interim data—a critical view 2005 PĂ©ter Bauer
Franz Koenig
Common Coauthors
Commonly Cited References
Action Title Year Authors # of times referenced
+ Adaptive designs for confirmatory clinical trials 2009 Frank Bretz
Franz Koenig
Werner Brannath
Ekkehard Glimm
Martin Posch
20
+ Evaluation of Experiments with Adaptive Interim Analyses 1994 PĂ©ter Bauer
Karl Kohne
19
+ Combining different phases in the development of medical treatments within a single trial 1999 PĂ©ter Bauer
Meinhard Kieser
18
+ PDF Chat Adaptive Sample Size Calculations in Group Sequential Trials 1999 Walter Lehmacher
Gernot Wassmer
18
+ Designed Extension of Studies Based on Conditional Power 1995 Michael A. Proschan
Sally Hunsberger
16
+ Adaptive Modifications of Hypotheses After an Interim Analysis 2001 Gerhard Hommel
16
+ PDF Chat Twenty‐five years of confirmatory adaptive designs: opportunities and pitfalls 2015 PĂ©ter Bauer
Frank Bretz
Vladimir Dragalin
Franz König
Gernot Wassmer
16
+ Adaptive Dunnett tests for treatment selection 2007 Franz Koenig
Werner Brannath
Frank Bretz
Martin Posch
15
+ On closed testing procedures with special reference to ordered analysis of variance 1976 Ruth Marcus
Eric Peritz
K. R. Gabriel
13
+ PDF Chat Adaptive clinical trial designs for European marketing authorization: a survey of scientific advice letters from the European Medicines Agency 2014 Amelie ElsĂ€ĂŸer
Jan Regnström
Thorsten Vetter
Franz Koenig
Robert Hemmings
Martina Greco
Marisa Papaluca‐Amati
Martin Posch
12
+ Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches 2001 Hans‐Helge MĂŒller
H. SchÀfer
11
+ Confirmatory adaptive designs with Bayesian decision tools for a targeted therapy in oncology 2009 Werner Brannath
Emmanuel Zuber
Michael Branson
Frank Bretz
Paul Gallo
Martin Posch
Amy Racine‐Poon
11
+ PDF Chat Testing and estimation in flexible group sequential designs with adaptive treatment selection 2005 Martin Posch
Franz Koenig
Michael Branson
Werner Brannath
Cornelia Dunger‐Baldauf
PĂ©ter Bauer
11
+ Modification of Sample Size in Group Sequential Clinical Trials 1999 Lu Cui
H. M. James Hung
Sue‐Jane Wang
10
+ A Multiple Testing Procedure for Clinical Trials 1979 Peter C. O’Brien
Thomas R. Fleming
10
+ Confirmatory Seamless Phase II/III Clinical Trials with Hypotheses Selection at Interim: General Concepts 2006 Frank Bretz
Heinz Schmidli
Franz König
Amy Racine
Willi Maurer
10
+ The reassessment of trial perspectives from interim data—a critical view 2005 PĂ©ter Bauer
Franz Koenig
9
+ An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints† 2010 Martin Jenkins
Andrew Stone
Christopher Jennison
9
+ Selection and bias—Two hostile brothers 2009 PĂ©ter Bauer
Franz Koenig
Werner Brannath
Martin Posch
9
+ PDF Chat Group Sequential Tests for Delayed Responses (with discussion) 2012 Lisa V. Hampson
Christopher Jennison
8
+ Adaptive Two Stage Designs and the Conditional Error Function 1999 Martin Posch
PĂ©ter Bauer
8
+ Group Sequential Methods with Applications to Clinical Trials 1999 Christopher Jennison
Bruce W. Turnbull
8
+ PDF Chat Methods for identification and confirmation of targeted subgroups in clinical trials: A systematic review 2015 Thomas Ondra
Alex Dmitrienko
Tim Friede
Alexandra GrĂĄf
Frank Miller
Nigel Stallard
Martin Posch
7
+ A Multiple Comparison Procedure for Comparing Several Treatments with a Control 1955 Charles W. Dunnett
7
+ A general statistical principle for changing a design any time during the course of a trial 2004 Hans‐Helge MĂŒller
H. SchÀfer
7
+ PDF Chat Adaptive designs in clinical trials: why use them, and how to run and report them 2018 Philip Pallmann
Alun Bedding
Babak Choodari‐Oskooei
Munyaradzi Dimairo
Laura Flight
Lisa V. Hampson
Jane Holmes
Adrian Mander
Lang’o Odondi
Matthew R. Sydes
7
+ A conditional error function approach for subgroup selection in adaptive clinical trials 2012 Tim Friede
Nick Parsons
Nigel Stallard
6
+ Adaptive Designs in Clinical Drug Development—An Executive Summary of the PhRMA Working Group 2006 Paul Gallo
Christy Chuang‐Stein
Vladimir Dragalin
Brenda Gaydos
Michael Krams
JosĂ© Cirı́aco Pinheiro
6
+ PDF Chat A generalized Dunnett test for multi-arm multi-stage clinical studies with treatment selection 2012 Dominic Magirr
Thomas Jaki
John Whitehead
6
+ Inference on Multiple Endpoints in Clinical Trials with Adaptive Interim Analyses 1999 Meinhard Kieser
PĂ©ter Bauer
Walter Lehmacher
6
+ Comments on the Draft Guidance on “Adaptive Design Clinical Trials for Drugs and Biologics” of the U.S. Food and Drug Administration 2010 Werner Brannath
Hans Ulrich Burger
Ekkehard Glimm
Nigel Stallard
Marc Vandemeulebroecke
Gernot Wassmer
6
+ The advantages and disadvantages of adaptive designs for clinical trials 2004 PĂ©ter Bauer
Werner Brannath
6
+ PDF Chat On model-based time trend adjustments in platform trials with non-concurrent controls 2022 Marta Bofill Roig
Pavla Krotka
Carl‐Fredrik Burman
Ekkehard Glimm
Stefan M. Gold
Katharina Hees
Peter Jacko
Franz Koenig
Dominic Magirr
Peter Mesenbrink
6
+ Sample Size Recalculation in Internal Pilot Study Designs: A Review 2006 Tim Friede
Meinhard Kieser
6
+ PDF Chat Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both 2017 Janet Woodcock
Lisa M. LaVange
6
+ The Design and Analysis of Sequential Clinical Trials. 1985 David Harrington
John Whitehead
6
+ Recursive Combination Tests 2002 Werner Brannath
Martin Posch
PĂ©ter Bauer
6
+ Issues in designing flexible trials 2003 Martin Posch
PĂ©ter Bauer
Werner Brannath
6
+ An improved Bonferroni procedure for multiple tests of significance 1986 R. John Simes
6
+ Adaptive Design: Results of 2012 Survey on Perception and Use 2014 Caroline C. Morgan
Susan Huyck
Martin Jenkins
Li Chen
Alun Bedding
Christopher S. Coffey
Brenda Gaydos
J. Kyle Wathen
6
+ PDF Chat The Evolution of Master Protocol Clinical Trial Designs: A Systematic Literature Review 2020 Elias Laurin Meyer
Peter Mesenbrink
Cornelia Dunger‐Baldauf
Hans‐JĂŒrgen FĂŒlle
Ekkehard Glimm
Yuhan Li
Martin Posch
Franz König
6
+ Two stage conditionally unbiased estimators of the selected mean 1989 Arthur Cohen
Harold B. Sackrowitz
5
+ PDF Chat Flexible sequential designs for multi‐arm clinical trials 2014 Dominic Magirr
Nigel Stallard
Thomas Jaki
5
+ PDF Chat Adaptive increase in sample size when interim results are promising: A practical guide with examples 2010 Cyrus R. Mehta
Stuart J. Pocock
5
+ Unbiased Estimation of Selected Treatment Means in Two‐Stage Trials 2008 Jack Bowden
Ekkehard Glimm
5
+ Estimation in flexible two stage designs 2005 Werner Brannath
Franz König
PĂ©ter Bauer
5
+ Optimal design of multi‐arm multi‐stage trials 2012 James Wason
Thomas Jaki
5
+ Type I error rate control in adaptive designs for confirmatory clinical trials with treatment selection at interim 2010 Martin Posch
Willi Maurer
Frank Bretz
5
+ When is a seamless study desirable? Case studies from different pharmaceutical sponsors 2014 Robert L. Cuffe
David Lawrence
Andrew Stone
Marc Vandemeulebroecke
5
+ PDF Chat A multi-stage drop-the-losers design for multi-arm clinical trials 2014 James Wason
Nigel Stallard
Jack Bowden
Christopher Jennison
5